Wellness Axis
Back Home{blogPostStyles.title}
Bringing Needed Structure to COVID-19 Drug Development
Bringing Needed Structure to COVID-19 Drug DevelopmentPosted on April 2nd, 2020 by Dr. Francis CollinsCaption: Molecular map showing interaction between the spike protein (gold) of the novel coronavirus and the peptidase domain (blue) of human angiotensin-converting enzyme 2 (ACE2). The ACE2 protein resides on the surface of cells in many parts of the human body, including the heart and lungs. These ACE inhibitors lower blood pressure by causing blood vessels to relax. Since the COVID-19 outbreak, many people have wondered whether taking ACE inhibitors would be helpful or detrimental against coronavirus infection. References:[1] Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.
Prev Article
More from the Wellness category
Next Article